What is Vivex?
Vivex operates as a pioneer in the field of regenerative medicine, focusing on the development of innovative treatment options designed to address tissue damage caused by trauma, injury, and chronic disease. By leveraging the extensive resources of the nation's oldest civilian tissue bank, the company bridges the gap between biological potential and clinical application. Their market position is defined by a unique ability to harness the body's inherent healing mechanisms, providing medical professionals with advanced tools that improve surgical outcomes and patient recovery trajectories. This focus on naturally sourced solutions places Vivex at the intersection of biotechnology and patient-centric care, addressing a critical need for sophisticated, reliable therapeutic interventions in modern healthcare.
How much funding has Vivex raised?
Vivex has raised a total of $21.9M across 3 funding rounds:
Series A
$6.6M
Private Equity
$6.3M
Debt
$9M
Series A (2015): $6.6M, investors not publicly disclosed
Private Equity (2017): $6.3M, investors not publicly disclosed
Debt (2017): $9M supported by Heritage Bank of Commerce
Key Investors in Vivex
Heritage Bank of Commerce
A California-based financial institution established in 1994 that provides specialized banking services and debt financing solutions tailored to the needs of growing business enterprises.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vivex?
With the recent influx of capital, Vivex is well-positioned to accelerate its research and development pipeline, potentially expanding its reach into new therapeutic indications. The strategic deployment of these funds will likely focus on enhancing the scalability of their tissue-based solutions and strengthening their market presence among surgical and clinical providers. As the company moves beyond its current growth phase, the emphasis will remain on maintaining the integrity of its supply chain and continuing to innovate within the regulatory framework of regenerative medicine. Future milestones will likely involve the optimization of clinical delivery systems and the pursuit of broader adoption across major healthcare networks, ensuring that their proprietary technologies become a standard of care for complex tissue repair.
See full Vivex company page
